Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | November 19, 2019 | November 21, 2019 |
| INCYTE CORPINCY · Entity 3182 | President, Global Head of R&D | September 15, 2026 | September 17, 2026 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | February 01, 2023 | February 01, 2023 |
| TURMERIC ACQUISITION CORP.TMPM · Entity 139875 | Director | October 15, 2020 | October 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date November 19, 2019 · Filed November 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-19 · Exercise / conversion · Acquired 7,500 · Balance 7,500 Row 2 · 2019-11-19 · Sale · Disposed 7,500 · Balance 0 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.59 · Expires 2025-11-04 | Direct | 63,833 |
Reported balance
After 2019-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-19 · Exercise / conversion · Disposed 7,500 · Balance 63,833 F2: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.
INCYTE CORP
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 186,157 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 2,957 · Balance 186,157 |
| Common StockSEC Table I · non-derivative | Direct | 190,708 |
Reported balance
After 2026-09-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-15 · Exercise / conversion · Acquired 4,551 · Balance 190,708 |
| Common StockSEC Table I · non-derivative | Direct | 197,185 |
Reported balance
After 2026-09-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Acquired 6,477 · Balance 197,185 |
| Common StockSEC Table I · non-derivative | Direct | 206,418 |
Reported balance
After 2026-09-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-15 · Exercise / conversion · Acquired 9,233 · Balance 206,418 |
| Common StockSEC Table I · non-derivative | Direct | 197,185 |
Reported balance
After 2026-09-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-15 · Sale · Disposed 9,233 · Balance 197,185 |
| Common StockSEC Table I · non-derivative | Direct | 183,200 |
Reported balance
After 2026-09-15 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-09-15 · Sale · Disposed 13,985 · Balance 183,200 F1: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.76 · Expires 2033-07-13 | Direct | 4,225 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,957 · Balance 4,225 F2: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.18 · Expires 2034-01-17 | Direct | 4,551 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 4,551 · Balance 4,551 F3: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.25 · Expires 2034-07-14 | Direct | 20,356 |
Reported balance
After 2026-09-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-15 · Exercise / conversion · Disposed 6,477 · Balance 20,356 F4: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.93 · Expires 2035-01-16 | Direct | 18,466 |
Reported balance
After 2026-09-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-15 · Exercise / conversion · Disposed 9,233 · Balance 18,466 F5: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
F2: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
F3: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
F4: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
F5: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.
Rubius Therapeutics, Inc.
Report date February 01, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,082 |
Reported balance
After 2023-02-01 transaction · row 1
1 source rowRow 1 · 2023-02-01 · Sale · Disposed 8,448 · Balance 66,082 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
TURMERIC ACQUISITION CORP.
Report date October 15, 2020 · Filed October 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fusion Pharmaceuticals Inc.
Report date June 04, 2024 · Filed June 04, 2024
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-04 · Disposition to issuer · Disposed 141,011 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2024 Filed Jun 4, 2024 17:31 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $8.15 | Not disclosed |
DisclosureSEC source: 0000950170-24-068904 · ownership.xml · derivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:31 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-068904 · ownership.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · security: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 18:04 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 21,843 | $0.00 Strike: $61.18 | $0.00 |
DisclosureSEC source: 0000879169-24-000034 · wk-form4_1705946668.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,843 Underlying: Common Stock · 21,843 shares Expires 2034-01-17 F1 · derivative.exercise_date: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 20,275 | $0.00 Strike: $61.76 | $0.00 |
DisclosureSEC source: 0001209191-23-042551 · doc4.xml · derivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,275 Underlying: Common Stock · 20,275 shares Expires 2033-07-13 F3 · derivative.exercise_date: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 9,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042551 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,068 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Pablo Cagnoni's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 14, 2023 RSU Grant, this includes an aggregate of 202,068 shares of common stock issuable pursuant to previously reported RSUs that have not vested. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 17:05 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001209191-23-037090 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 18:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 179,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034977 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,613 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years beginning June 1 2026, subject to Pablo Cagnoni's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 05, 2023 Filed Jun 21, 2023 20:00 UTC Amendment | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 192,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038745 · doc4a.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,400 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years beginning June 1, 2026, subject to Pablo Cagnoni's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. The original Form 4, filed on June 7, 2023, is being amended by this Form 4/A to correct an administrative error that incorrectly reported the number of units granted, originally reported as 179,613 instead of 192,400. Read SEC document |
| February 01, 2023 Filed Feb 1, 2023 21:41 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 8,448 | $0.25 | $2,112.00 |
DisclosureSEC source: 0001104659-23-009465 · tm235103-4_4seq1.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,082 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 21:51 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008874 · tm235103-2_4seq1.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. F5 · derivative.expiration_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 21:51 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 7,240 | $0.24 | $1,744.84 |
DisclosureSEC source: 0001104659-23-008874 · tm235103-2_4seq1.xml · nonDerivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,530 F2 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.26, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 21:51 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-008874 · tm235103-2_4seq1.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 29, 2023 Filed Jan 31, 2023 21:51 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionRestricted Stock Units · Derivative | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008874 · tm235103-2_4seq1.xml · derivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 21,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022. F4 · derivative.expiration_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2023 Filed Jan 31, 2023 21:51 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 21,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-008874 · tm235103-2_4seq1.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 14, 2022 Filed Jun 22, 2022 19:05 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-22-038767 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 21:20 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 6,730 | $6.57 | $44,236.29 |
DisclosureSEC source: 0001179110-22-000697 · edgar.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,520 F2 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.72, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 21:20 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000697 · edgar.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. F6 · derivative.expiration_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 21:20 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 365,000 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0001179110-22-000697 · edgar.xml · derivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,000 Underlying: Common Stock · 365,000 shares Expires 2032-01-30 F5 · derivative.exercise_date: 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 21:20 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionRestricted Stock Units · Derivative | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000697 · edgar.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 21,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022. F4 · derivative.expiration_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 21:20 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 21,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-000697 · edgar.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 16, 2021 Filed Feb 14, 2022 19:52 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GiftCommon Stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001203 · edgar.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,320 Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 16:13 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001209191-21-038567 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 4, 2022 or (ii) the 2022 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. Read SEC document |
| April 26, 2021 Filed Feb 14, 2022 19:52 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001203 · edgar.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,520 Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 20:26 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantRestricted Stock Units · Derivative | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001126 · edgar.xml · derivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The shares underlying the restricted stock units will vest in four equal annual installments beginning on January 29, 2022. F3 · derivative.expiration_date: The shares underlying the restricted stock units will vest in four equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 20:26 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001179110-21-001126 · edgar.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: 25% of this option shall vest on January 29, 2022, then in 12 equal quarterly installments thereafter. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 06:36 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017873 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments beginning on July 18, 2020. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:14 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | PurchaseCommon Stock | 21,000 | $4.70 | $98,693.70 |
DisclosureSEC source: 0001104659-20-047001 · a4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Read SEC document |
| January 31, 2020 Filed Feb 3, 2020 21:48 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-20-010064 · a4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: 25% of this option shall vest on January 31, 2021, then in 12 equal quarterly installments thereafter. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-19-057596 · doc4.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,833 Underlying: Common Shares · 7,500 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 7,500 | $62.00 | $465,000.00 |
DisclosureSEC source: 0001209191-19-057596 · doc4.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 7,500 | $5.59 | $41,925.00 |
DisclosureSEC source: 0001209191-19-057596 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-19-056372 · doc4.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,333 Underlying: Common Shares · 7,500 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 7,500 | $55.00 | $412,500.00 |
DisclosureSEC source: 0001209191-19-056372 · doc4.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 7,500 | $5.59 | $41,925.00 |
DisclosureSEC source: 0001209191-19-056372 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-19-054774 · doc4.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,833 Underlying: Common Shares · 7,500 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 7,500 | $52.00 | $390,000.00 |
DisclosureSEC source: 0001209191-19-054774 · doc4.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 7,500 | $5.59 | $41,925.00 |
DisclosureSEC source: 0001209191-19-054774 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:04 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $43.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016845 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001104659-19-005603 · a4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-30 F1 · derivative.exercise_date: 25% of this option shall vest on January 31, 2020, then in 12 equal quarterly installments thereafter. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:11 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 193,400 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001104659-18-065519 · a4.xml · derivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,400 Underlying: Common Stock · 193,400 shares Expires 2028-10-30 F2 · derivative.exercise_date: Upon the achievement of a performance milestone, 50% of this option shall vest upon the achievement of a second performance milestone and 50% of this option shall vest upon the achievement of a third performance milestone. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:11 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 164,400 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001104659-18-065519 · a4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,400 Underlying: Common Stock · 164,400 shares Expires 2028-10-30 F1 · derivative.exercise_date: Upon the achievement of a performance milestone, 25% of this option shall vest effective as of October 31, 2019, then in 12 equal quarterly installments thereafter. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 22:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,684 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · derivative · entry 6 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,333 Underlying: Common Shares · 1,684 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 22:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,684 | $62.00 | $104,408.00 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · nonDerivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 22:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 1,684 | $5.59 | $9,413.56 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · nonDerivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 22:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,816 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,017 Underlying: Common Shares · 5,816 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 22:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,816 | $62.00 | $360,592.00 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 22:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 5,816 | $5.59 | $32,511.44 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016868 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2018-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0000899243-17-015166 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017. Read SEC document |
| October 18, 2016 Filed Oct 20, 2016 21:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-16-032070 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2026-10-18 F1 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning October 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.